All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
During the EHA2021 Virtual Congress, the MPN Hub spoke with Tiziano Barbui, Papa Giovanni XXIII Hospital, Bergamo, IT. We asked, What are the long-term effects of COVID-19 in patients with myeloproliferative neoplasms (MPN)?
What are the long-term effects of COVID-19 in patients with MPN?
In this video, Barbui discusses the findings from a European observational study on the epidemiology of COVID-19 in patients with MPN. The study consisted of 180 patients from European countries and looked at mortality rates and incidence of thrombosis.
Myeloproliferative neoplasms, thrombosis, and COVID-19
Myeloproliferative neoplasms (MPN) are associated with a high prevalence of thrombosis at diagnosis: 28.6% in polycythemia vera (PV), 20.7% in essential thrombocytosis, and 9.5% in...
Essential thrombocythemia is associated with a higher risk of thrombosis during COVID-19
COVID-19 has been reported to damage multiple organ systems, primarily the respiratory system, which contributes to the high mortality rate among patients. In...
Subscribe to get the best content related to MPN delivered to your inbox